Incanthera (AQSE:INC) Buildings And Improvements : £0.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Buildings And Improvements?

Incanthera Buildings And Improvements Historical Data

The historical data trend for Incanthera's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Buildings And Improvements Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Buildings And Improvements

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Buildings And Improvements	Get a 7-Day Free Trial			-	-	-	-	-

Incanthera Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines